Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors

In this open label phase II trial combination therapy with the anti-PD-L1 antibody atezolizumab and the anti-TIGIT antibody tiragolumab will be investigated in patients with localized HNSCC who will undergo surgery, advanced or metastatic MSI-H cancer, PD-1 resistant metastatic melanoma, and patients with a locally advanced or metastatic solid tumor who, in the opinion of the investigator, based on available clinical data, may benefit from treatment with anti-PD-L1 and anti-TIGIT immunotherapy.

Trial Details

NCT ID

NCT05483400

Phase

PHASE2

Sponsor

University Medical Center Groningen

Status

RECRUITING

Cancer Type

Melanoma

Interventions

Tiragolumab and atezolizumab

Locations (sample)

Groningen, Netherlands|53.21917,6.56667

Key Eligibility Criteria

Tumor lesion(s) of which a histological biopsy can be safely obtained according to standard clinical care procedures.
Measurable disease, as defined by RECIST v1.1. Previously irradiated lesions should be discarded as target lesions.
Participate in the GE-269-001 CD8 investigational imaging trial provided that there are slots is that trial.
Signed informed consent.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →